Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 285 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SUTENT Clear all
Terminated Phase 1Phase 2 Interventional Results available

Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome

NCT00673816
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome
Interventions
Sunitinib Malate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 22, 2026, 5:33 AM EDT
Active, not recruiting Not applicable Interventional

Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

NCT01582204
View directory record Official record
Conditions
Renal Cancer
Interventions
124IcG250
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

NCT00731211
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pazopanib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
17
States / cities
San Francisco, California • Fort Myers, Florida • Lakeland, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 22, 2026, 5:33 AM EDT
Terminated Phase 2 Interventional Results available

Sunitinib and Capecitabine for First Line Colon Cancer

NCT00961571
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
sunitinib and capecitabine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 22, 2026, 5:33 AM EDT
Terminated Phase 2 Interventional Results available

A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma

NCT00982657
View directory record Official record
Conditions
Solid Tumor
Interventions
CVX-060 + sunitinib, Sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
Scottsdale, Arizona • Santa Monica, California • Southaven, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 22, 2026, 5:33 AM EDT
Terminated Phase 1 Interventional

Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer

NCT00524186
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
fluorouracil, irinotecan hydrochloride, leucovorin calcium, sunitinib malate, flow cytometry, pharmacological study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Not applicable Interventional Results available

Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer

NCT00849186
View directory record Official record
Conditions
Kidney Cancer
Interventions
sunitinib malate, neoadjuvant therapy, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2015 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00698815
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Pemetrexed Disodium, Sunitinib Malate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
129
States / cities
Anaheim, California • Arroyo Grande, California • Baldwin Park, California + 90 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 22, 2026, 5:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

NCT00417885
View directory record Official record
Conditions
Breast Neoplasms
Interventions
exemestane, sunitinib malate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

NCT00375674
View directory record Official record
Conditions
Kidney Neoplasms
Interventions
Sunitinib malate, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
12
States / cities
Los Angeles, California • Atlanta, Georgia • Marrero, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer

NCT00137423
View directory record Official record
Conditions
Carcinoma, Renal Cell Metastasis
Interventions
SU011248 (sunitinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Stanford, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 30, 2009 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)

NCT00075218
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
Placebo, SU011248
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
27
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Oct 22, 2026, 5:33 AM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

NCT01026337
View directory record Official record
Conditions
Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
mutation analysis, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging, sunitinib malate, immunohistochemistry staining method, laboratory biomarker analysis
Genetic · Other · Procedure + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 22, 2026, 5:33 AM EDT
Terminated Phase 3 Interventional

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

NCT01582672
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Standard Treatment, AGS-003
Drug · Biological
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
88
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 1 Interventional

A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma

NCT00422344
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
RAD001, Sunitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2010 · Synced Oct 22, 2026, 5:33 AM EDT
Terminated Phase 1Phase 2 Interventional

Temodar and Sutent as Therapy for Melanoma

NCT00304200
View directory record Official record
Conditions
Metastatic Malignant Melanoma
Interventions
Temozolomide and SU11248
Drug
Lead sponsor
Northern California Melanoma Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC

NCT00616109
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
sunitinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 22, 2026, 5:33 AM EDT
Terminated Not applicable Interventional Results available

Evaluation of Patients With Bulky GIST Using Sunitinib

NCT01054911
View directory record Official record
Conditions
Tumor
Interventions
Sunitinib, Surgery
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 22, 2026, 5:33 AM EDT
Terminated Phase 2 Interventional Results available

Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

NCT00495625
View directory record Official record
Conditions
Liver Cancer
Interventions
Sunitinib Malate
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 22, 2026, 5:33 AM EDT
Available No phase listed Expanded access

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

NCT06948955
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
Interventions
Bezuclastinib, Sunitinib
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 5:33 AM EDT
Terminated Phase 2 Interventional Results available

Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)

NCT00782834
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Nilotinib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00425386
View directory record Official record
Conditions
Kidney Cancer
Interventions
erlotinib hydrochloride, sunitinib malate, biopsy
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Portland, Oregon • Salem, Oregon
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Not applicable Interventional Results available

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

NCT00656669
View directory record Official record
Conditions
Breast Cancer
Interventions
sunitinib alone, sunitinib plus paclitaxel, doxorubicin and cyclophosphamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

NCT01068769
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
regorafenib
Drug
Lead sponsor
Suzanne George, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 22, 2026, 5:33 AM EDT